The company
Bicara Therapeutics Inc.
BCAX · Nasdaq
BCAX stood above a rising 150-day average in 46 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 23.3% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 5
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $9.6M
- Insider sales, 12 months
- $17.9M
- Officials’ trades on record
- 0
- Institutions holding
- 167 (+27)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 46 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Ryan CohlheppPresident, COO & Interim CEO | sold | 14,058at $22.77 | 8 Sep 2026filed 10 Sep 2026 |
| Ryan CohlheppPresident, COO & Interim CEO | sold | 3,442at $23.43 | 8 Sep 2026filed 10 Sep 2026 |
| Ryan CohlheppPresident and COO | sold | 18,750at $27.98 | 10 Aug 2026filed 12 Aug 2026 |
| Claire MazumdarChief Executive Officer | sold | 10,000at $27.98 | 10 Aug 2026filed 12 Aug 2026 |
| Ivan HyepChief Financial Officer | sold | 12,500at $27.97 | 10 Aug 2026filed 12 Aug 2026 |
| Claire MazumdarChief Executive Officer | sold | 9,972at $28.42 | 10 Jul 2026filed 14 Jul 2026 |
| Claire MazumdarChief Executive Officer | sold | 28at $29.68 | 10 Jul 2026filed 14 Jul 2026 |
| Ryan CohlheppPresident and COO | sold | 536at $29.00 | 9 Jul 2026filed 10 Jul 2026 |
| Ivan HyepChief Financial Officer | sold | 22,757at $28.60 | 8 Jul 2026filed 10 Jul 2026 |
| Ivan HyepChief Financial Officer | sold | 4,413at $29.82 | 8 Jul 2026filed 10 Jul 2026 |
| Ivan HyepChief Financial Officer | sold | 830at $30.31 | 8 Jul 2026filed 10 Jul 2026 |
| Ryan CohlheppPresident and COO | sold | 22,833at $28.76 | 8 Jul 2026filed 10 Jul 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026 | 7,255,993$215.4M | 00.0% |
| Siren, L.L.C.reduced · filed 13 Aug 2026 | 5,602,970$166.4M | -200,000−3.4% |
| Vestal Point Capital, LPreduced · filed 14 Aug 2026 | 5,250,000$155.9M | -175,000−3.2% |
| Deep Track Capital, LPadded · filed 14 Aug 2026 | 4,100,000$121.7M | +37,500+0.9% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 3,848,090$114.2M | +1,004,383+35.3% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 3,171,015$94.0M | +3,171,015 |
| RED TREE MANAGEMENT, LLCreduced · filed 22 Jul 2026 | 3,163,517$93.9M | -6,992−0.2% |
| TPG GP A, LLCunchanged · filed 14 Aug 2026 | 3,010,425$89.4M | 00.0% |
| Royalty Pharma Sub-Manager, LLCunchanged · filed 14 Aug 2026 | 2,388,150$60.6M | 00.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 2,216,639$65.8M | +442,419+24.9% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.